Galapagos NV (GLPG) has released an update. Galapagos NV is presenting promising preliminary data from their Phase 1/2 studies on innovative CAR-T therapies, GLPG5101 and GLPG5201, at the EBMT congress
Galapagos NV (GLPG) has released an update. Galapagos NV is presenting promising preliminary data from their Phase 1/2 studies on innovative CAR-T therapies, GLPG5101 and GLPG5201, at the EBMT congress
Galapagos announced that four abstracts, including two oral presentations on encore preliminary clinical and translational data for its seven-day vein-to-vein CAR-T product candidates GLPG5101 and GLPG5201, will be presented at
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by
BofA downgraded Galapagos to Underperform from Neutral with a price target of $31, down from $41. The analyst is concerned that the shares remain a “value trap.” Galapagos’ enterprise value
האנליסט חושש שמניית החברה עשויה להיות “מלכודת ערך”, כלומר נראית כאילו היא יכולה להיות עסקה טובה אך היא לא. ל-Galapagos היה ערך חברה שלילי—בעצם, הערך הכולל של החברה פחות החובות